Next-generation CAD therapies and the competitive pipeline — the development of new biologic and small molecule treatments targeting the canine atopic dermatitis immune pathway beyond the established IL-31 (Cytopoint) and JAK (Apoquel) mechanisms — creating the competitive pharmaceutical pipeline that will reshape the canine atopic dermatitis treatment market within the Canine...